# CoreMap

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coremap

- Industry: Healthcare
- Headquarters: Burlington, US
- Website: www.coremapmedical.com/
- Total disclosed funding: $68M
- Latest round: Series C (Jun 18, 2026)
- Investors on record: 3

## About

CoreMap Inc. specializes in developing innovative diagnostic technologies to enhance the treatment of atrial fibrillation, a prevalent heart arrhythmia. Their advanced mapping technology aids physicians in real-time visualization of patient conditions, improving treatment accuracy. CoreMap Inc. was founded in 2016 and is headquartered in Burlington, US. The company focuses on advancing diagnostic technology for atrial fibrillation treatment. In June 2026, CoreMap Inc. raised USD 35.51 million in series C funding led by Medtronic. The co-founders of the company are Peter Spector and CEO Sarah Kalil. CoreMap develops advanced diagnostic technologies aimed at improving the treatment of atrial fibrillation (AF), which can lead to serious health complications. Their flagship product utilizes innovative mapping technology, allowing physicians to visualize AF in real-time, thus enhancing patient assessment and treatment. This technology is designed for higher spatial resolution and sample density, addressing key challenges in AF mapping and supporting better patient outcomes. CoreMap primarily targets healthcare providers, including hospitals and specialized clinics, particularly in North America and select international markets prioritizing advanced cardiac care.CoreMap's revenue model is based on direct sales to healthcare providers, focusing on partnerships with hospitals and medical institutions specializing in cardiology. The company engages in B2B transactions, supplying its diagnostic technology for clinical use. Their pricing structure reflects the value delivered through enhanced patient outcomes and operational efficiencies. The innovative AF mapping technology forms a crucial part of cardiology departments within hospitals, and CoreMap aims to broaden its customer base within the healthcare sector. The company plans to utilize the June 2026 funding to accelerate product launch and support its next stage of growth.

## Funding rounds

- Series C, Jun 18, 2026, $36M — Medtronic Ventures
- Series B, Jan 27, 2022, $23M — Qure Ventures
- Series A, Sep 9, 2020, $8.9M — OrbiMed Advisors, Qure Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Qure Ventures (https://capitalatlas.ai/funds/qure-ventures) — Series A, Series B
- Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series C